Ginkgo Bioworks Holdings (DNA) Acquisitions (2021 - 2024)

Ginkgo Bioworks Holdings (DNA) posted Acquisitions of $5.4 million for Q1 2024, up 157.8% on a QoQ basis from -$9.3 million in Q4 2021.

Ginkgo Bioworks Holdings (DNA) Acquisitions (2021 - 2024) Analysis & Trends

Ginkgo Bioworks Holdings' Acquisitions history runs 2 years deep, the most recent figure standing at $5.4 million for Q1 2024.

Quarterly Acquisitions changed N/A year-over-year to $5.4 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $5.4 million (changed N/A YoY) and the FY2024 annual result came in at $5.4 million, changed N/A from the prior year.
Acquisitions was $5.4 million for Q1 2024 at Ginkgo Bioworks Holdings, up from -$9.3 million in the prior quarter.
Across five years, Acquisitions topped out at $21.4 million in Q3 2021 and bottomed at -$9.3 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Ginkgo Bioworks Holdings	517.16 Mn	373.30 Mn	16.38 Mn	-

Download Data